NCT02554812 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 28
- group Id
- BG004
- value
- 35
- group Id
- BG005
- value
- 21
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 21
- group Id
- BG008
- value
- 11
- group Id
- BG009
- value
- 11
- group Id
- BG010
- value
- 12
- group Id
- BG011
- value
- 12
- units
- Participants
- groups
- description
- During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.
- id
- BG000
- title
- Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab
- description
- During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG001
- title
- Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab
- description
- During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG002
- title
- Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab
- description
- During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG003
- title
- Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG004
- title
- Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG005
- title
- Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG006
- title
- Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG007
- title
- Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
- id
- BG008
- title
- Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab
- description
- During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
- id
- BG009
- title
- Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab
- description
- During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
- id
- BG010
- title
- Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab
- description
- During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
- id
- BG011
- title
- Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.22
- value
- 64.14
- group Id
- BG001
- spread
- 10.85
- value
- 60.74
- group Id
- BG002
- spread
- 11.81
- value
- 61.52
- group Id
- BG003
- spread
- 10.82
- value
- 63.71
- group Id
- BG004
- spread
- 11.80
- value
- 61.09
- group Id
- BG005
- spread
- 14.59
- value
- 53.33
- group Id
- BG006
- spread
- 12.74
- value
- 59.40
- group Id
- BG007
- spread
- 11.05
- value
- 65.24
- group Id
- BG008
- spread
- 10.05
- value
- 65.27
- group Id
- BG009
- spread
- 4.06
- value
- 69.55
- group Id
- BG010
- spread
- 12.55
- value
- 54.17
- group Id
- BG011
- spread
- 10.68
- value
- 64.75
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 21
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 7
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 7
- title
- Female
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 20
- group Id
- BG004
- value
- 31
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 12
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 4
- group Id
- BG010
- value
- 7
- group Id
- BG011
- value
- 5
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 1
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 32
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 19
- group Id
- BG008
- value
- 11
- group Id
- BG009
- value
- 11
- group Id
- BG010
- value
- 11
- group Id
- BG011
- value
- 11
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 16
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 8
- group Id
- BG010
- value
- 9
- group Id
- BG011
- value
- 8
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The safety analysis set included all participants who received at least one dose of study drug.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 29
- group Id
- BG003
- value
- 28
- group Id
- BG004
- value
- 35
- group Id
- BG005
- value
- 21
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 21
- group Id
- BG008
- value
- 11
- group Id
- BG009
- value
- 11
- group Id
- BG010
- value
- 12
- group Id
- BG011
- value
- 12
- units
- Participants
- groups
- description
- During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.
- id
- BG000
- title
- Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab
- description
- During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG001
- title
- Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab
- description
- During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG002
- title
- Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab
- description
- During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG003
- title
- Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG004
- title
- Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG005
- title
- Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG006
- title
- Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.
- id
- BG007
- title
- Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab
- description
- During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
- id
- BG008
- title
- Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab
- description
- During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.
- id
- BG009
- title
- Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab
- description
- During Phase 1b participants received PF-04518600 0.3 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
- id
- BG010
- title
- Combination B Phase 1b: PF-04518600 0.3 mg/kg + Avelumab
- description
- During Phase 1b participants received PF-04518600 1.0 mg/kg IV Q2W with 10 mg/kg of avelumab administered IV Q2W. Phase 2 in the melanoma cohort was not planned.
- id
- BG011
- title
- Combination B Phase 1b: PF-04518600 1.0 mg/kg + Avelumab
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.22
- value
- 64.14
- group Id
- BG001
- spread
- 10.85
- value
- 60.74
- group Id
- BG002
- spread
- 11.81
- value
- 61.52
- group Id
- BG003
- spread
- 10.82
- value
- 63.71
- group Id
- BG004
- spread
- 11.80
- value
- 61.09
- group Id
- BG005
- spread
- 14.59
- value
- 53.33
- group Id
- BG006
- spread
- 12.74
- value
- 59.40
- group Id
- BG007
- spread
- 11.05
- value
- 65.24
- group Id
- BG008
- spread
- 10.05
- value
- 65.27
- group Id
- BG009
- spread
- 4.06
- value
- 69.55
- group Id
- BG010
- spread
- 12.55
- value
- 54.17
- group Id
- BG011
- spread
- 10.68
- value
- 64.75
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 21
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 9
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 7
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 7
- title
- Female
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 20
- group Id
- BG004
- value
- 31
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 12
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 4
- group Id
- BG010
- value
- 7
- group Id
- BG011
- value
- 5
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 1
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 32
- group Id
- BG005
- value
- 19
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 19
- group Id
- BG008
- value
- 11
- group Id
- BG009
- value
- 11
- group Id
- BG010
- value
- 11
- group Id
- BG011
- value
- 11
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 2
- group Id
- BG011
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 26
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 16
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 8
- group Id
- BG010
- value
- 9
- group Id
- BG011
- value
- 8
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 2
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The safety analysis set included all participants who received at least one dose of study drug.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle